Sou Hu Cai Jing·2026-01-02 18:26Core Viewpoint - Xinhua Pharmaceutical has recently received drug registration certificates for two new products, which are expected to enhance its market competitiveness and revenue potential in the coming year [2][3]. Group 1: Stock Performance - As of December 31, 2025, Xinhua Pharmaceutical's stock closed at 15.41 yuan, down 2.53% from the previous week's 15.81 yuan [1]. - The stock reached a high of 15.85 yuan and a low of 15.40 yuan during the week [1]. - The company's current total market capitalization is 10.629 billion yuan, ranking 49th out of 150 in the chemical pharmaceutical sector and 1817th out of 5181 in the A-share market [1]. Group 2: Product Approvals - Xinhua Pharmaceutical has obtained a drug registration certificate for isopropyl phenol injection, classified as a Class 4 chemical drug, aimed at treating spasmodic pain in the digestive, biliary, urinary, and gynecological systems, with an expected sales revenue of approximately 900 million yuan in 2024 for public medical institutions [2][3]. - The company has also received a registration certificate for valsartan capsules, also classified as a Class 4 chemical drug, intended for the treatment of mild to moderate primary hypertension, with an anticipated sales revenue of about 1.82 billion yuan in 2024 for public medical institutions [2][3]. - The approval of these two products is expected to enhance the company's product competitiveness, although sales may be influenced by policy and market factors, introducing some uncertainty [2].